glp 1 drugs shortage Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s 📣 Important GLP1 Update from

Additionally, we stated that when these products are administered, they are the primary treatment being administered to a patient and thus, are not integral, ancillary, supportive, dependent, or adjunctive to any primary C-APC services

If you are pregnant/nursing, taking medication (including thyroid hormones), or have a medical condition (including thyroid disorder), consult your healthcare practitioner before taking this product

It is illustrative, not a promise of results

Similarly, in the SURMOUNT-1 trial of tirzepatide, lean mass was reduced by 5.67 kg or 10.9% from baseline, with a weight reduction of 22.1 kg or 20.9% (with the highest dose), yielding a fraction of weight lost from lean mass of 25.7% [175]

Lachman et al., 2006

Herbal nanomedicines: recent advancements, challenges, opportunities and regulatory overview